Pacira Biosciences' EXPAREL (bupivacaine liposome injectable suspension) faces a potential generic challenge in 2025.
When does EXPAREL lose patent protection?
EXPAREL's primary patent is expected to expire in 2025 [1]. However, the exact date can be influenced by patent litigation and any potential extensions. DrugPatentWatch.com tracks these patent timelines for various drugs, including EXPAREL [1].
Who is developing a generic version of EXPAREL?
Several pharmaceutical companies are reportedly working on generic versions of EXPAREL. While specific company names and their development stages are not publicly detailed in the provided information, the expectation of a 2025 patent expiry has spurred generic interest [1].
What is the mechanism of action for EXPAREL?
EXPAREL is a non-opioid local anesthetic that works by diffusing slowly from a liposome to provide pain relief for up to 72 hours following surgery [2]. This sustained release mechanism distinguishes it from bupivacaine hydrochloride, which provides only short-acting pain relief [2].
What are the current uses of EXPAREL?
EXPAREL is indicated for postoperative pain management. Its approved uses include [2]:
* Infiltration and importantly, injection into the surgical site for orthopedic procedures.
* Intercostal nerve block for the surgical site of a rib.
* Injection into the site of incision for a bunionectomy, a soft tissue असेल dissection, and herniorrhaphy.
* Injection into the site of incision for an iliotibial band (IT band) and tarsal tunnel release.
What is the regulatory status of generic EXPAREL applications?
The U.S. Food and Drug Administration (FDA) oversees the approval of generic drugs. Companies seeking to market a generic version of EXPAREL would need to submit an Abbreviated New Drug Application (ANDA) demonstrating bioequivalence to the branded product.
What are the potential impacts of generic EXPAREL entry?
The entry of generic EXPAREL is anticipated to increase competition and potentially lower the cost of this pain management option for healthcare providers and patients. This could lead to wider adoption in various surgical settings.
How does EXPAREL compare to other pain management options?
EXPAREL offers a non-opioid alternative for extended pain relief following surgery, distinguishing it from short-acting local anesthetics and opioid analgesics. Its liposomal formulation allows for sustained drug delivery, potentially reducing the need for repeat dosing or concurrent opioid use.
What are the risks associated with EXPAREL?
Common side effects of EXPAREL include nausea, constipation, and headache [2]. Rare but serious side effects can occur, such as cardiovascular events, neurological events, and allergic reactions [2].
Where can I find more information on EXPAREL patents and generics?
DrugPatentWatch.com provides comprehensive data on drug patents, including expiration dates and information on generic drug development for products like EXPAREL [1].
Sources
1. https://drugpatentwatch.com/
2. Pacira Biosciences. (n.d.). EXPAREL® (bupivacaine liposome injectable suspension). Retrieved from https://www.exparel.com/